Focused On-demand Library for Acetylcholine receptor subunit delta

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q07001

UPID:

ACHD_HUMAN

Alternative names:

Alternative UPACC:

Q07001; A8K661; B4DT92; Q52LH4

Background:

The Acetylcholine receptor subunit delta plays a pivotal role in neuromuscular signaling, facilitating communication between nerve cells and muscles. This receptor is integral for muscle contraction, responding to acetylcholine by undergoing extensive conformational changes that open an ion-conducting channel across the plasma membrane.

Therapeutic significance:

Mutations in the Acetylcholine receptor subunit delta are linked to several forms of congenital myasthenic syndrome and lethal multiple pterygium syndrome, diseases characterized by muscle weakness and developmental abnormalities. Understanding the receptor's function and its genetic variants offers a pathway to targeted treatments for these neuromuscular disorders.